Cosmos Health Launches Subscription Model
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) has launched a subscription-based purchasing model for its proprietary consumer health brands, starting with NOOR Collagen in the United States. Early data for this product show a repeat purchase rate above 60% and margins in excess of 50%.
The company plans to roll out the subscription model across additional brands and global markets. According to Cosmos Health, the approach is intended to generate recurring revenue, enhance cash-flow visibility, enable product bundling, offer access to nutrition and wellness guidance, and deepen customer loyalty and lifetime value.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- NOOR Collagen subscription repeat purchase rate above 60% in the US
- Subscription margins currently in excess of 50% for NOOR Collagen
- New subscription model launched for proprietary consumer health brands
- Planned global expansion of the subscription model across more products and markets
Negative
- None.
Market reaction: COSM +12.02% on subscription model launch
On the day this news was published, COSM gained 12.02%, reflecting a significant positive market reaction. Argus tracked a peak move of +31.9% during that session. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $20.31M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 09 | Share repurchase update | Positive | -1.0% | Expanded buybacks to 4.14M shares under $5M repurchase authorization. |
| Jul 08 | Share repurchase update | Positive | +2.8% | Buybacks surpassed 4.06M shares within ongoing $5M program. |
| Jul 07 | Share repurchase update | Positive | -4.9% | Additional 230,000 shares repurchased, lifting total to 3.87M shares. |
| Jul 07 | Preliminary earnings & buybacks | Positive | -4.9% | Record Q2 and H1 2026 revenue with ongoing $5M buyback program. |
| Jul 06 | Share repurchase update | Positive | +13.8% | Repurchases reached 3.64M shares within authorized $5M program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent buyback and record‑revenue announcements have often seen mixed to negative next‑day price reactions despite generally positive fundamentals.
Regulatory & Risk Context
Reported short positioning appears relatively low, suggesting limited near-term squeeze dynamics and a more typical volatility profile driven by fundamentals and news flow.
An effective S-3 shelf of this size allows Cosmos Health to issue various securities over time, which can facilitate capital raises but may be dilutive when used.
Key Terms
recurring revenue financial
lifetime value financial
cash-flow visibility financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Subscription model already launched with NOOR Collagen in the United States
- Early data shows a repeat purchase rate above
60% at high margins in excess of50% - Model is designed to drive stronger loyalty, greater lifetime value, and more predictable cash-flow visibility
- Company plans to extend the subscription model to additional Cosmos Health products globally, with further initiatives already underway
CHICAGO, July 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has launched a subscription-based purchasing model for its proprietary consumer health brands.
The model is currently live with NOOR Collagen in the United States, with encouraging early results that include a repeat purchase rate above
The Company plans to extend the subscription model to a broader range of its consumer health products across its brands and markets globally, with further initiatives already underway. Cosmos Health expects the model to offer several benefits:
- Recurring revenue: Converts one-time purchases into ongoing subscriptions, generating predictable, recurring revenue.
- Cash-flow visibility: Improves forward visibility into revenue and demand over time.
- Product bundling: Lets consumers combine multiple products in a single subscription, increasing convenience and average order value.
- Personalized guidance: Gives subscribers access to nutritionists and wellness consultants to tailor product selections to their goals.
- Stronger customer relationships: Deepens loyalty and lifetime value through an ongoing, direct relationship with consumers.
The Company expects to provide additional details, including sales, repeat purchase and retention rates, and margins, as the model matures.
Greg Siokas, CEO of Cosmos Health, stated: "A subscription model is a natural next step in deepening our relationship with consumers and building recurring revenue across our brands. The early response to our NOOR Collagen subscription in the United States has been encouraging, and by pairing our science-driven products with personalized guidance, we believe we can drive stronger loyalty, greater lifetime value, and more predictable revenue as we grow.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
